The data will be based on the abstract titled “Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer” (abstract no. 140). The company intends to publish the data in a peer-reviewed journal later this year.